Rune Häckert Christensen

Rune Häckert Christensen

Auto-generated profile, based on publicly available information

Rune Häckert Christensen

Copenhagen University Hospital – Rigshospitalet

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Neurology
Verified
Journal Article
Open access
RCRune H. Christensen
Rune H. Christensen
HAHåkan Ashina
Håkan Ashina
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
YZYixin Zhang
Yixin Zhang
DTDaniel Tolnai
Daniel Tolnai
MAMessoud Ashina
Messoud Ashina
Structural imaging can offer insights into the cortical morphometry of migraine, which might reflect adaptations to recurring nociceptive messaging. This study compares cortical morphometry between a large sample of people with migraine and healthy controls, as well as across migraine subtypes. Adult participants with migraine and age-matched and sex-matched healthy controls attended a single MRI session with magnetization-prepared rapid acquisition gradient echo and fluid-attenuated inversion recovery sequences at 3T. Cortical surface area, thickness, and volume were compared between participants with migraine (including subgroups) and healthy controls across the whole cortex within FreeSurfer and reported according to the Desikan-Killiany atlas. The analysis used cluster-determining thresholds of p < 0.0001 and cluster-wise thresholds of p < 0.05, adjusted for age, sex, and total intracranial volume. A total of 296 participants with migraine (mean age 41.6 years ± 12.4 SD, 261 women) and 155 healthy controls (mean age 41.1 years ± 11.7 SD, 133 women) were included. Among the participants with migraine, 180 (63.5%) had chronic migraine, 103 (34.8%) had migraine with aura, and 88 (29.7%) experienced a migraine headache during the scan. The total cohort of participants with migraine had reduced cortical surface area in the left insula, compared with controls (p < 0.0001). Furthermore, participants with chronic migraine (n = 180) exhibited reduced surface area in the left insula (p < 0.0001) and increased surface area in the right caudal anterior cingulate cortex (p < 0.0001), compared with controls. We found no differences specific to participants with aura or ongoing migraine headache. Post hoc tests revealed a positive correlation between monthly headache days and surface area within the identified anterior cingulate cluster (p = 0.014). The identified cortical changes in migraine were limited to specific pain processing regions, including the insula and caudal anterior cingulate gyrus, and were most notable in participants with chronic migraine. These findings suggest persistent cortical changes associated with migraine. The REFORM study (clinicaltrials.gov identifier: NCT04674020).

17 March 2025 in Cephalalgia
Verified
Journal Article
Open access
CRChristopher L. Robinson
Christopher L. Robinson
RCRune H. Christensen
Rune H. Christensen
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
FAFaisal Mohammad Amin
Faisal Mohammad Amin
AYAiling Yang
Ailing Yang
SASait Ashina
Sait Ashina
Background: Cervicogenic headache is a rare headache disorder which is garnering increasing clinical and research interest, but whose prevalence and clinical phenotype is surrounded by uncertainty. We found it timely to systematically appraise the current literature on prevalence, relative frequency, and clinical features of cervicogenic headache in population- and clinic-based settings. Methods: PubMed and Embase were searched for observational, population- and clinic-based studies published between 1 January 1942 and 3 September 2024 that reported on the prevalence and relative frequency of cervicogenic headache, diagnosed according to the International Classification of Headache Disorders. The titles, abstracts, and full text-articles were screened by two independent investigators. To estimate prevalence and pooled relative frequency of cervicogenic headache across clinic- and population-based studies, random-effects meta-analyses were conducted. The study was pre-registered on PROSPERO (identifier: CRD42024498128) and reported in accordance with the Guidelines for Meta-Analyses of Observational Studies in Epidemiology. Results: Three studies met the inclusion criteria from the International Classification of Headache Disorders for diagnosing cervicogenic headache. One was population-based reporting on the prevalence and two were clinic-based reporting on the relative frequency of cervicogenic headache among adult patients who were evaluated for headache in a tertiary care unit. The one population study reported a prevalence of 3.9% with females representing 77.8% of those affected. In the two clinic-based studies, the relative frequency was found to be 3.1% (95%, CI, 2.6–3.8) amongst the adult outpatient population of 3165 patients evaluated for headache, with women representing 80.8% (95%, CI, 71.9–87.4). Conclusions: Based on this meta-analysis, data on the prevalence and relative frequency of cervicogenic headache are limited. The scarcity of data stresses the need for further research into cervicogenic headache, the diagnostic criteria, and its current position in the International Classification of Headache Disorders.

14 May 2025 in Cephalalgia
Verified
Journal Article
Open access
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
RCRune H. Christensen
Rune H. Christensen
EGEmil Gozalov
Emil Gozalov
ZHZahra Hakimzadeh
Zahra Hakimzadeh
AMAnna G. Melchior
Anna G. Melchior
HAHåkan Ashina
Håkan Ashina
Objective: To determine whether intravenous infusion of substance P elicits headache and arterial dilation in healthy adults. Methods: In a double-blind, placebo-controlled, two-way crossover study, we randomly allocated healthy adults to receive either substance P (1.5 pmol/kg/min) or placebo (isotonic saline) by 20-minute intravenous infusion on separate experiment days. The primary endpoint was the incidence of headache within 12 hours after the infusion. Other endpoints included the area under the curve (AUC) for headache intensity scores over the 12-hour observation period and AUC changes in the superficial temporal artery (STA) diameter from baseline to 120 minutes post-infusion. Results: Twenty-one participants underwent randomization and completed both experiment days. Headache was reported by 15 (71%) of 21 participants following substance P, compared with two (10%) after placebo ( p  < 0.001). The AUC for headache intensity scores was significantly higher after substance P infusion than after placebo ( p  = 0.03). In addition, there was a significant STA diameter increase with substance P, compared with placebo ( p  = 0.005). Conclusions: Among healthy adults, substance P infusion elicited headache and arterial dilation. These findings support a role for substance P in headache pathogenesis and encourage further investigation in migraine and other headache disorders. Additional research is also needed to explore new therapeutic strategies targeting substance P or its downstream signaling. Trial Registration: CT identifier: NCT06632080.

6 June 2025 in Cephalalgia
Verified
Journal Article
Open access
BCBasit Ali Chaudhry
Basit Ali Chaudhry
SYSamaira Younis
Samaira Younis
RMRoberta Messina
Roberta Messina
DGDavid García-Azorín
David García-Azorín
NKNazia Karsan
Nazia Karsan
FAFaisal Mohammad Amin
Faisal Mohammad Amin
Background: Structural imaging offers insight into migraine pathogenesis. Magnetic resonance imaging (MRI) morphometry plays a crucial role in identifying these alterations, yet the clinical significance remains debated. While gray matter volume and cortical curvature are commonly analyzed, cortical thickness offers a more direct measure of cytoarchitectural differences and neuroplastic changes in migraine. Advanced structural MRI techniques, including surface-based morphometry and voxel-based morphometry, have provided insights into cortical thickness alterations in migraine. These methods enable high-resolution assessment of brain morphometry, revealing dynamic changes associated with migraine phases and treatment. Methods: This narrative review synthesizes findings from cortical thickness studies, focusing on methodological approaches, variations in imaging sequences and study designs, including cross-sectional and longitudinal studies. Results: Studies using surface-based morphometry (i.e. SBM) and voxel-based morphometry (i.e. VBM) have reported inconsistent findings. Increased thickness is frequently observed in pain-processing regions, such as the somatosensory cortex, insula and anterior cingulate cortex reflecting hyperexcitability or maladaptive neuroplasticity. by contrast, cortical thinning has been noted in regions such as the orbitofrontal cortex, posterior cingulate cortex and visual cortex, suggesting neuronal loss or impaired cortical integrity. Differences between episodic and chronic migraine further highlight progressive structural changes associated with disease burden. Emerging evidence also suggests that preventive treatments, including calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A, may reverse some of these cortical alterations, particularly in treatment responders. Conclusions: Cortical thickness analysis provides valuable insights into migraine pathophysiology, offering a potential biomarker for disease progression and treatment response. However, inconsistencies across studies highlight the need for standardized MRI protocols and larger longitudinal investigations to clarify the clinical relevance of cortical thickness changes in migraine.

1 August 2025 in Cephalalgia
Verified
Journal Article
Open access
BABerkay Alpay
Berkay Alpay
RCRune Häckert Christensen
Rune Häckert Christensen
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
MAMessoud Ashina
Messoud Ashina
HAHåkan Ashina
Håkan Ashina
Substance P, a neuropeptide associated with pain and inflammation, has been implicated in migraine pathophysiology through its action within the trigeminovascular system. This narrative review summarizes current evidence on the synthesis, release, receptor binding and downstream effects of substance P. It integrates preclinical and clinical findings to reassess its therapeutic relevance. Substance P is released from primary afferent neurons and acts on neurokinin-1 receptors, which are widely expressed in both peripheral tissues and central pain-processing regions. In the meninges, substance P contributes to vasodilation, plasma protein extravasation, mast cell degranulation and immune cell recruitment, all of which facilitate neurogenic inflammation and possibly lower the activation threshold of meningeal nociceptors. In the central nervous system, substance P promotes excitatory neurotransmission, potentiates glutaminergic activity and attenuates inhibitory GABAergic signaling, cumulatively amplifying pain transmission. Preclinical studies consistently demonstrate that neurokinin-1 receptors antagonists inhibit substance P-induced responses, such as neurogenic inflammation and neuronal activation, supporting their therapeutic potential. However, randomized controlled trials with neurokinin-1 receptors antagonists were not superior to placebo in treating migraine. A re-appraisal of these trials reveal that the disappointing results might be due to methodologic shortcomings, including underpowered samples and suboptimal efficacy endpoints. A recent randomized, double-blind, placebo-controlled, two-way crossover study showed that intravenous infusion of substance P is potent inducer of headache and arterial dilation in healthy adults. These findings align with the established biological functions of substance P and warrant renewed therapeutic interest. Advances in translational research, particularly those emphasizing direct measurement of meningeal nociceptor activity and refined clinical trial design, might overcome past limitations and clarify the role of substance P in migraine. The dismissal of substance P signaling as a therapeutic target might thus have been premature. Renewed efforts might uncover novel therapeutic strategies, offering hope for patients with migraine who remain unresponsive to existing treatment.

23 May 2025 in Cephalalgia
Verified
Journal Article
Open access
EGEmil Gozalov
Emil Gozalov
WKWilliam K. Karlsson
William K. Karlsson
RCRune H. Christensen
Rune H. Christensen
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
MHMalene B. Hansen
Malene B. Hansen
HAHåkan Ashina
Håkan Ashina
Objective: To determine whether serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) concentrations differ between adults with migraine and healthy controls. Methods: This single-center, cross-sectional study was conducted from September 2020 to June 2022. Adults diagnosed with migraine and healthy controls were enrolled. Serum GFAP and NfL concentrations were quantified using an ultra-sensitive single-molecule array platform. Analyses were adjusted for potential confounders, including age, sex, body mass index and smoking status. Results: We assessed serum samples from 603 participants with migraine and 154 controls. Serum GFAP concentrations were 6.8% higher in the overall migraine group compared to controls (95% confidence interval = 0.4–13.5%; P = 0.036). Conversely, serum NfL concentrations did not differ between participants with migraine and controls (difference: −1.4%; 95% confidence interval = −7.9 to 5.6%; p = 0.68). Neither serum GFAP, nor NfL concentrations varied according to migraine subtype or headache status at the time of blood sampling. Conclusions: Our findings demonstrate a modest yet statistically significant increase in serum GFAP among adults with migraine, independent of migraine subtype, whereas serum NfL levels were comparable to those of controls. Further research is needed to clarify the neurobiological mechanisms underlying elevated serum GFAP in migraine.